Global Kidney Cancer Therapeutics Market Research Report 2023

Kidney Cancer Therapeutics Market

Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Kidney Cancer Therapeutics market research.

The kidney cancer therapeutics market is evolving rapidly to address the treatment needs of patients diagnosed with kidney cancer, also known as renal cell carcinoma (RCC). This market encompasses a range of therapies, including targeted therapies, immunotherapies, and combination treatments. The increasing incidence of kidney cancer, advancements in understanding its molecular basis, and the emergence of novel treatment options are driving market growth. Targeted therapies that inhibit specific pathways implicated in kidney cancer progression, along with immunotherapies that harness the immune system's response, are gaining prominence. As research continues and personalized treatment approaches gain traction, the kidney cancer therapeutics market is expected to expand, offering new hope for improved outcomes and quality of life for patients with this challenging disease.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Kidney Cancer Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Kidney Cancer Therapeutics Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Kidney Cancer Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Surgery

1.2.3 Immunotherapy

1.2.4 Targeted Therapy

1.2.5 Other

1.3 Market by Application

1.3.1 Global Kidney Cancer Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Renal Cell Carcinoma

1.3.3 Renal Pelvis Cancer

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Kidney Cancer Therapeutics Market Perspective (2018-2029)

2.2 Kidney Cancer Therapeutics Growth Trends by Region

2.2.1 Global Kidney Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Kidney Cancer Therapeutics Historic Market Size by Region (2018-2023)

2.2.3 Kidney Cancer Therapeutics Forecasted Market Size by Region (2024-2029)

2.3 Kidney Cancer Therapeutics Market Dynamics

2.3.1 Kidney Cancer Therapeutics Industry Trends

2.3.2 Kidney Cancer Therapeutics Market Drivers

2.3.3 Kidney Cancer Therapeutics Market Challenges

2.3.4 Kidney Cancer Therapeutics Market Restraints

3.1 Global Top Kidney Cancer Therapeutics Players by Revenue

3.1.1 Global Top Kidney Cancer Therapeutics Players by Revenue (2018-2023)

3.1.2 Global Kidney Cancer Therapeutics Revenue Market Share by Players (2018-2023)

3.2 Global Kidney Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Kidney Cancer Therapeutics Revenue

3.4 Global Kidney Cancer Therapeutics Market Concentration Ratio

3.4.1 Global Kidney Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Therapeutics Revenue in 2022

3.5 Kidney Cancer Therapeutics Key Players Head office and Area Served

3.6 Key Players Kidney Cancer Therapeutics Product Solution and Service

3.7 Date of Enter into Kidney Cancer Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Kidney Cancer Therapeutics Historic Market Size by Type (2018-2023)

4.2 Global Kidney Cancer Therapeutics Forecasted Market Size by Type (2024-2029)

5.1 Global Kidney Cancer Therapeutics Historic Market Size by Application (2018-2023)

5.2 Global Kidney Cancer Therapeutics Forecasted Market Size by Application (2024-2029)

6.1 North America Kidney Cancer Therapeutics Market Size (2018-2029)

6.2 North America Kidney Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Kidney Cancer Therapeutics Market Size by Country (2018-2023)

6.4 North America Kidney Cancer Therapeutics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Kidney Cancer Therapeutics Market Size (2018-2029)

7.2 Europe Kidney Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Kidney Cancer Therapeutics Market Size by Country (2018-2023)

7.4 Europe Kidney Cancer Therapeutics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Kidney Cancer Therapeutics Market Size (2018-2029)

8.2 Asia-Pacific Kidney Cancer Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2018-2023)

8.4 Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Kidney Cancer Therapeutics Market Size (2018-2029)

9.2 Latin America Kidney Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Kidney Cancer Therapeutics Market Size by Country (2018-2023)

9.4 Latin America Kidney Cancer Therapeutics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Kidney Cancer Therapeutics Market Size (2018-2029)

10.2 Middle East & Africa Kidney Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2018-2023)

10.4 Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Merck

11.1.1 Merck Company Detail

11.1.2 Merck Business Overview

11.1.3 Merck Kidney Cancer Therapeutics Introduction

11.1.4 Merck Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.1.5 Merck Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Kidney Cancer Therapeutics Introduction

11.2.4 Novartis Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.2.5 Novartis Recent Development

11.3 Bristol-Myers Squibb

11.3.1 Bristol-Myers Squibb Company Detail

11.3.2 Bristol-Myers Squibb Business Overview

11.3.3 Bristol-Myers Squibb Kidney Cancer Therapeutics Introduction

11.3.4 Bristol-Myers Squibb Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.3.5 Bristol-Myers Squibb Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Kidney Cancer Therapeutics Introduction

11.4.4 Pfizer Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.4.5 Pfizer Recent Development

11.5 Roche

11.5.1 Roche Company Detail

11.5.2 Roche Business Overview

11.5.3 Roche Kidney Cancer Therapeutics Introduction

11.5.4 Roche Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.5.5 Roche Recent Development

11.6 Amgen

11.6.1 Amgen Company Detail

11.6.2 Amgen Business Overview

11.6.3 Amgen Kidney Cancer Therapeutics Introduction

11.6.4 Amgen Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.6.5 Amgen Recent Development

11.7 Aveo Pharmaceuticals

11.7.1 Aveo Pharmaceuticals Company Detail

11.7.2 Aveo Pharmaceuticals Business Overview

11.7.3 Aveo Pharmaceuticals Kidney Cancer Therapeutics Introduction

11.7.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.7.5 Aveo Pharmaceuticals Recent Development

11.8 Bayer

11.8.1 Bayer Company Detail

11.8.2 Bayer Business Overview

11.8.3 Bayer Kidney Cancer Therapeutics Introduction

11.8.4 Bayer Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.8.5 Bayer Recent Development

11.9 Exelixis

11.9.1 Exelixis Company Detail

11.9.2 Exelixis Business Overview

11.9.3 Exelixis Kidney Cancer Therapeutics Introduction

11.9.4 Exelixis Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.9.5 Exelixis Recent Development

11.10 Eisai

11.10.1 Eisai Company Detail

11.10.2 Eisai Business Overview

11.10.3 Eisai Kidney Cancer Therapeutics Introduction

11.10.4 Eisai Revenue in Kidney Cancer Therapeutics Business (2018-2023)

11.10.5 Eisai Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Kidney Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Surgery

    Table 3. Key Players of Immunotherapy

    Table 4. Key Players of Targeted Therapy

    Table 5. Key Players of Other

    Table 6. Global Kidney Cancer Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Kidney Cancer Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Kidney Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 9. Global Kidney Cancer Therapeutics Market Share by Region (2018-2023)

    Table 10. Global Kidney Cancer Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 11. Global Kidney Cancer Therapeutics Market Share by Region (2024-2029)

    Table 12. Kidney Cancer Therapeutics Market Trends

    Table 13. Kidney Cancer Therapeutics Market Drivers

    Table 14. Kidney Cancer Therapeutics Market Challenges

    Table 15. Kidney Cancer Therapeutics Market Restraints

    Table 16. Global Kidney Cancer Therapeutics Revenue by Players (2018-2023) & (US$ Million)

    Table 17. Global Kidney Cancer Therapeutics Market Share by Players (2018-2023)

    Table 18. Global Top Kidney Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2022)

    Table 19. Ranking of Global Top Kidney Cancer Therapeutics Companies by Revenue (US$ Million) in 2022

    Table 20. Global 5 Largest Players Market Share by Kidney Cancer Therapeutics Revenue (CR5 and HHI) & (2018-2023)

    Table 21. Key Players Headquarters and Area Served

    Table 22. Key Players Kidney Cancer Therapeutics Product Solution and Service

    Table 23. Date of Enter into Kidney Cancer Therapeutics Market

    Table 24. Mergers & Acquisitions, Expansion Plans

    Table 25. Global Kidney Cancer Therapeutics Market Size by Type (2018-2023) & (US$ Million)

    Table 26. Global Kidney Cancer Therapeutics Revenue Market Share by Type (2018-2023)

    Table 27. Global Kidney Cancer Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 28. Global Kidney Cancer Therapeutics Revenue Market Share by Type (2024-2029)

    Table 29. Global Kidney Cancer Therapeutics Market Size by Application (2018-2023) & (US$ Million)

    Table 30. Global Kidney Cancer Therapeutics Revenue Market Share by Application (2018-2023)

    Table 31. Global Kidney Cancer Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 32. Global Kidney Cancer Therapeutics Revenue Market Share by Application (2024-2029)

    Table 33. North America Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 34. North America Kidney Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 35. North America Kidney Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 36. Europe Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. Europe Kidney Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 38. Europe Kidney Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Asia-Pacific Kidney Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 41. Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2024-2029) & (US$ Million)

    Table 42. Latin America Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Latin America Kidney Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Kidney Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Merck Company Detail

    Table 49. Merck Business Overview

    Table 50. Merck Kidney Cancer Therapeutics Product

    Table 51. Merck Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 52. Merck Recent Development

    Table 53. Novartis Company Detail

    Table 54. Novartis Business Overview

    Table 55. Novartis Kidney Cancer Therapeutics Product

    Table 56. Novartis Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 57. Novartis Recent Development

    Table 58. Bristol-Myers Squibb Company Detail

    Table 59. Bristol-Myers Squibb Business Overview

    Table 60. Bristol-Myers Squibb Kidney Cancer Therapeutics Product

    Table 61. Bristol-Myers Squibb Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 62. Bristol-Myers Squibb Recent Development

    Table 63. Pfizer Company Detail

    Table 64. Pfizer Business Overview

    Table 65. Pfizer Kidney Cancer Therapeutics Product

    Table 66. Pfizer Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 67. Pfizer Recent Development

    Table 68. Roche Company Detail

    Table 69. Roche Business Overview

    Table 70. Roche Kidney Cancer Therapeutics Product

    Table 71. Roche Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 72. Roche Recent Development

    Table 73. Amgen Company Detail

    Table 74. Amgen Business Overview

    Table 75. Amgen Kidney Cancer Therapeutics Product

    Table 76. Amgen Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 77. Amgen Recent Development

    Table 78. Aveo Pharmaceuticals Company Detail

    Table 79. Aveo Pharmaceuticals Business Overview

    Table 80. Aveo Pharmaceuticals Kidney Cancer Therapeutics Product

    Table 81. Aveo Pharmaceuticals Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 82. Aveo Pharmaceuticals Recent Development

    Table 83. Bayer Company Detail

    Table 84. Bayer Business Overview

    Table 85. Bayer Kidney Cancer Therapeutics Product

    Table 86. Bayer Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 87. Bayer Recent Development

    Table 88. Exelixis Company Detail

    Table 89. Exelixis Business Overview

    Table 90. Exelixis Kidney Cancer Therapeutics Product

    Table 91. Exelixis Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 92. Exelixis Recent Development

    Table 93. Eisai Company Detail

    Table 94. Eisai Business Overview

    Table 95. Eisai Kidney Cancer Therapeutics Product

    Table 96. Eisai Revenue in Kidney Cancer Therapeutics Business (2018-2023) & (US$ Million)

    Table 97. Eisai Recent Development

    Table 98. Research Programs/Design for This Report

    Table 99. Key Data Information from Secondary Sources

    Table 100. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Kidney Cancer Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Kidney Cancer Therapeutics Market Share by Type: 2022 VS 2029

    Figure 3. Surgery Features

    Figure 4. Immunotherapy Features

    Figure 5. Targeted Therapy Features

    Figure 6. Other Features

    Figure 7. Global Kidney Cancer Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 8. Global Kidney Cancer Therapeutics Market Share by Application: 2022 VS 2029

    Figure 9. Renal Cell Carcinoma Case Studies

    Figure 10. Renal Pelvis Cancer Case Studies

    Figure 11. Other Case Studies

    Figure 12. Kidney Cancer Therapeutics Report Years Considered

    Figure 13. Global Kidney Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Kidney Cancer Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Kidney Cancer Therapeutics Market Share by Region: 2022 VS 2029

    Figure 16. Global Kidney Cancer Therapeutics Market Share by Players in 2022

    Figure 17. Global Top Kidney Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Kidney Cancer Therapeutics Revenue in 2022

    Figure 19. North America Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Kidney Cancer Therapeutics Market Share by Country (2018-2029)

    Figure 21. United States Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Kidney Cancer Therapeutics Market Share by Country (2018-2029)

    Figure 25. Germany Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Kidney Cancer Therapeutics Market Share by Region (2018-2029)

    Figure 33. China Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Kidney Cancer Therapeutics Market Share by Country (2018-2029)

    Figure 41. Mexico Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Kidney Cancer Therapeutics Market Share by Country (2018-2029)

    Figure 45. Turkey Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Kidney Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Merck Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 48. Novartis Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 50. Pfizer Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 51. Roche Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 52. Amgen Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 53. Aveo Pharmaceuticals Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 54. Bayer Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 55. Exelixis Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 56. Eisai Revenue Growth Rate in Kidney Cancer Therapeutics Business (2018-2023)

    Figure 57. Bottom-up and Top-down Approaches for This Report

    Figure 58. Data Triangulation

    Figure 59. Key Executives Interviewed